These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 14999632)

  • 1. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.
    Pankey GA; Sabath LD
    Clin Infect Dis; 2004 Mar; 38(6):864-70. PubMed ID: 14999632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections.
    Rhee KY; Gardiner DF
    Clin Infect Dis; 2004 Sep; 39(5):755-6. PubMed ID: 15356797
    [No Abstract]   [Full Text] [Related]  

  • 3. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria].
    Candel González FJ
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
    Krueger WA; Unertl KE
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y; Sunagawa M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative urinary bactericidal activity of oral antibiotics against gram-positive pathogens].
    Bedenić B; Budimir A; Gverić A; Plecko V; Vranes J; Bubonja-Sonje M; Kalenić S
    Lijec Vjesn; 2012; 134(5-6):148-55. PubMed ID: 22930932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].
    Araos R; García P; Chanqueo L; Labarca J
    Rev Chilena Infectol; 2012 Apr; 29(2):127-31. PubMed ID: 22689024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
    Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid--a review of the first oxazolidinone.
    Norrby R
    Expert Opin Pharmacother; 2001 Feb; 2(2):293-302. PubMed ID: 11336587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamic activity of daptomycin.
    Safdar N; Andes D; Craig WA
    Antimicrob Agents Chemother; 2004 Jan; 48(1):63-8. PubMed ID: 14693519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria.
    Yin J; Meng Q; Cheng D; Fu J; Luo Q; Liu Y; Yu Z
    Appl Microbiol Biotechnol; 2020 May; 104(9):3771-3780. PubMed ID: 32157424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections.
    Faghih O; Zhang Z; Ranade RM; Gillespie JR; Creason SA; Huang W; Shibata S; Barros-Álvarez X; Verlinde CLMJ; Hol WGJ; Fan E; Buckner FS
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.
    Neu HC
    Drugs; 1993; 45 Suppl 3():54-8. PubMed ID: 7689452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.
    Nemeth J; Oesch G; Kuster SP
    J Antimicrob Chemother; 2015 Feb; 70(2):382-95. PubMed ID: 25266070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.